[BioS] SillaJen Presents Interim Results of Phase 1 Solid Tumor Trial of TTK/PLK1 at ESMO
Predicted impact: Low
Interim early-stage trial data presented at a conference; preclinical-stage news is vague.
Predicted impact: Low
Interim early-stage trial data presented at a conference; preclinical-stage news is vague.
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.